.Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A02B_DrugsForPepticUlcerAndGastroOesophagealRefluxDis.A02BC02_Pantoprazole.Pantoprazole

Information

Pantoprazole is a proton pump inhibitor (PPI) used for the treatment of gastroesophageal reflux disease (GERD), Zollinger-Ellison syndrome, and other acid-related disorders. It works by inhibiting the gastric H+/K+-ATPase enzyme, thereby reducing gastric acid secretion. It is approved for use in many countries and is available both as oral and intravenous formulations.

Pharmacokinetics

Pharmacokinetic parameters reported for healthy adult volunteers following single intravenous dose of pantoprazole.

References

1. Pettersen, G, et al., & Litalien, C (2009). Population pharmacokinetics of intravenous pantoprazole in paediatric intensive care patients. British journal of clinical pharmacology 67(2) 216–227. DOI:10.1111/j.1365-2125.2008.03328.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/19173681

2. Kearns, GL, et al., & Paul, J (2008). Single-dose pharmacokinetics of oral and intravenous pantoprazole in children and adolescents. Journal of clinical pharmacology 48(11) 1356–1365. DOI:10.1177/0091270008321811 PUBMED:https://pubmed.ncbi.nlm.nih.gov/18664620

3. McCann, S, et al., & Gonzalez, D (2023). Population Pharmacokinetics of Posaconazole in Immune-Compromised Children and Assessment of Target Attainment in Invasive Fungal Disease. Clinical pharmacokinetics 62(7) 997–1009. DOI:10.1007/s40262-023-01254-2 PUBMED:https://pubmed.ncbi.nlm.nih.gov/37179512

Revisions

• 06/2025 initial generated model